iMDx Welcomes New VP Marketing to Prepare for Commercial Transplant Assay Launch

Core Insights - Insight Molecular Diagnostics Inc. (iMDx) has appointed Steven Tahmooressi as Vice President of Marketing to lead the marketing efforts for its upcoming clinical kitted assay, GraftAssureDx, set to launch in 2026 [2][5][6] - The company aims to democratize access to molecular diagnostic testing, focusing initially on transplant rejection testing through its GraftAssure family of assays, which includes GraftAssureCore and GraftAssureIQ [5][11][14] - The addressable market for kitted transplant rejection testing is estimated at $1 billion, with GraftAssure tests measuring donor-derived cell-free DNA (dd-cfDNA), a key biomarker for transplant rejection [8][10] Company Overview - iMDx, formerly known as Oncocyte Corp., is a precision diagnostics technology company headquartered in Nashville, Tennessee, since June 2025 [12] - The company specializes in quantifying dd-cfDNA, which is widely recognized as a biomarker for transplant rejection [11][12] - GraftAssureCore is currently reimbursed by Medicare and performed at iMDx's CLIA-certified laboratory in Nashville, while GraftAssureIQ is available for research use only [7][14] Leadership and Experience - Steven Tahmooressi brings over 25 years of healthcare industry experience, having previously held significant roles at Astellas Pharma, Abbott Laboratories, and Bristol-Myers Squibb [3][4][6] - His expertise includes leading successful product launches in transplantation, oncology, and immunology across various global markets [5][6][9] Product Development and Market Strategy - iMDx is preparing for FDA authorization of GraftAssureDx in 2025, which will be a clinical molecular diagnostic test kit aimed at improving testing access for kidney transplant patients [5][7][14] - The company has invested three years in developing its kitted product for transplant rejection testing, indicating a strong commitment to this market segment [5][8]